Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM2-NivEnt: Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies
NCT03838042Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- May 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and entinostat in central nervous system tumor and solid tumor, sponsored by Heidelberg University Hospital. Primary endpoints: Dose Limiting Toxicity at 5 weeks and Best response (CR or PR) at 24 weeks. Started May 2020; status: recruiting.
02
Drugs
nivolumabentinostat
03
Conditions
central nervous system tumorsolid tumor
Beyond the preview
Go deeper on NCT03838042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838042.